Education
About Us
Working with TipRanks
Follow Us
Aquestive Therapeutics (AQST)
NASDAQ:AQST
AQST Stock Chart & Stats
$5.80
-$0.11(-3.57%)
At close: 4:00 PM EST
$5.80
-$0.11(-3.57%)
Day’s Range― - ―
52-Week Range$2.12 - $7.55
Previous CloseN/A
Volume606.88K
Average Volume (3M)2.48M
Market Cap
$707.62M
Enterprise Value$617.97M
Total Cash (Recent Filing)$129.06M
Total Debt (Recent Filing)$128.86M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Mar 10, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding122,003,110
10 Day Avg. Volume2,196,434
30 Day Avg. Volume2,484,190
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-5.13
Price to Sales (P/S)5.36
P/FCF Ratio-8.60
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue14.24
Enterprise Value/Gross Profit23.62
Enterprise Value/Ebitda-12.71
Forecast
1Y Price Target
$9.80Price Target Upside68.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.62
Revenue Forecast (FY)$44.88M
Bulls Say, Bears Say
Bulls Say
Commercial ReadinessManagement continues to advance its comprehensive US launch readiness efforts, with key commercial hires underway following the strategic appointment of a new Chief Commercial Officer.
FDA Approval ProspectsThe FDA's decision to waive the advisory committee (AdCom) is a meaningful risk-mitigating factor and should reinforce investor confidence in a favorable FDA decision.
Market PotentialAnaphylm could generate peak sales of over $280 million by 2034, with prospects for faster-than-expected uptake and higher peak sales remaining high.
Bears Say
Aquestive Therapeutics News
AQST FAQ
What was Aquestive Therapeutics’s price range in the past 12 months?
Aquestive Therapeutics lowest stock price was $2.12 and its highest was $7.55 in the past 12 months.
What is Aquestive Therapeutics’s market cap?
Aquestive Therapeutics’s market cap is $707.62M.
When is Aquestive Therapeutics’s upcoming earnings report date?
Aquestive Therapeutics’s upcoming earnings report date is Mar 10, 2026 which is in 78 days.
How were Aquestive Therapeutics’s earnings last quarter?
Aquestive Therapeutics released its earnings results on Nov 05, 2025. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.128 by -$0.012.
Is Aquestive Therapeutics overvalued?
According to Wall Street analysts Aquestive Therapeutics’s price is currently Undervalued.
Does Aquestive Therapeutics pay dividends?
Aquestive Therapeutics does not currently pay dividends.
What is Aquestive Therapeutics’s EPS estimate?
Aquestive Therapeutics’s EPS estimate is -0.13.
How many shares outstanding does Aquestive Therapeutics have?
Aquestive Therapeutics has 122,003,110 shares outstanding.
What happened to Aquestive Therapeutics’s price movement after its last earnings report?
Aquestive Therapeutics reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.128. Following the earnings report the stock price went up 2.167%.
Which hedge fund is a major shareholder of Aquestive Therapeutics?
Currently, no hedge funds are holding shares in AQST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aquestive Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.80 (68.97% Upside)
$9.80 (68.97% Upside)
Blogger Sentiment
Bullish
AQST Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.1%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
59.34%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
48.75%
Trailing 12-Months
Company Description
Aquestive Therapeutics
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
AQST Company Deck
AQST Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call emphasized strategic progress towards Anaphylm's FDA approval and significant financing achievements, fostering optimism about the product's launch and market potential. However, financial challenges such as increased net loss and decreased revenue highlight ongoing operational hurdles.View all AQST earnings summariesAQST Stock 12 Month Forecast
Average Price Target
$9.80
▲(68.97% Upside)
Technical Analysis
Emergent Biosolutions
―
SIGA Technologies
―
Esperion
―
Organogenesis Holdings
―
Evolus
―
Ownership Overview
2.81% Insiders
6.76% Mutual Funds
26.81% Other Institutional Investors
56.17% Public Companies and
Individual Investors